FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Jared Isaacman Confirmed as NASA Administrator, Becomes 15th Leader of U.S. Space Agency 
South Korea Exports Surge in January on AI Chip Demand, Marking Fastest Growth in 4.5 Years 
South Korea Factory Activity Hits 18-Month High as Export Demand Surges 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Gold Prices Pull Back After Record Highs as January Rally Remains Strong 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Gold and Silver Prices Plunge as Trump Taps Kevin Warsh for Fed Chair 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
Fujirebio Holding is now doubling down on developing blood tests to detect Alzheimer’s against which blockbuster therapy is expected soon.
The tiny Tokyo-based diagnostics firm, a unit of H.U. Group Holdings, which has a market value of $1.2 billion, developed the first US-approved spinal fluid test for Alzheimer’s.
According to Goki Ishikawa, the CEO of Fujirebio, the firm is boosting its lineup of reagents used to detect Alzheimer’s biomarkers in blood tests. It aims to file these tests for approval in the US as early as 2023.
Ishikawa said that the lineups offered by industry leaders are still limited, so they are rushing to create a solid lineup of tests.
